Evidence map›Paper›PMID 25792630›Full record

ReviewThe European respiratory journal2015

Towards tuberculosis elimination: an action framework for low-incidence countries.

Knut Lönnroth, Giovanni Battista Migliori, Ibrahim Abubakar, Lia D'Ambrosio, Gerard de Vries, Roland Diel, Paul Douglas, Dennis Falzon, Marc-Andre Gaudreau, Delia Goletti and 63 more

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The European respiratory journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06127641 (Rehabilitation of People With Post-tuberculosis Lung Disease), which is not on this map. Cited by 333 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
333citing papers in PubMed, 14 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06127641 narecruitingnot on this mapstarted 2023, after this paper: background citation

Rehabilitation of People With Post-tuberculosis Lung Disease

TypeinterventionalSponsorCentro Universitário Augusto MottaRan2023 to 2027Enrolled40ConditionsPulmonary TuberculosisArmsStandard care plus pulmonary rehabilitation, Standard Care
3 · Its place in the literature

Who cites it

333 citing papers in PubMed, 14 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Tuberculosis Treatment Outcome and Predictors in Africa: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2021
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.American journal of respiratory and critical care medicine · 2019
    Guideline
  14. Effectiveness of interventions for reducing TB incidence in countries with low TB incidence: a systematic review of reviews.European respiratory review : an official journal of the European Respiratory Society · 2019
    Pooled it
  15. Trial
  16. Trial
  17. Article
  18. Breaking barriers: Implementation of a tuberculosis preventive treatment protocol among newly eligible populations with promising results.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  19. Article
  20. Article

273 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

73 authors.

Knut LönnrothGlobal TB Programme, World Health Organization, Geneva, Switzerland Both authors contributed equally.
Giovanni Battista MiglioriWHO Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, IRCCS, Tradate, Italy Both authors contributed equally.
Ibrahim AbubakarTB Section, University College London and Public Health England, London, UK.
Lia D'AmbrosioWHO Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, IRCCS, Tradate, Italy.
Gerard de VriesKNCV Tuberculosis Foundation, The Hague, The Netherlands.
Roland DielUniversity Hospital Schleswig Holstein, Institute for Epidemiology, Kiel, Germany.
Paul DouglasGlobal Health Borders Refugee and Onshore Services, Dept of Immigration and Border Protection, Sydney, Australia.
Dennis FalzonGlobal TB Programme, World Health Organization, Geneva, Switzerland.
Marc-Andre GaudreauCentre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Montreal, QC, Canada.
Delia GolettiNational Institute for Infectious Diseases, Rome, Italy.
Edilberto R González OchoaResearch and Surveillance Group on TB, Leprosy and ARI, Epidemiology Board, Institute of Tropical Medicine "Pedro Kourí", Havana, Cuba.
Philip LoBueDivision of TB Elimination, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Alberto MatteelliGlobal TB Programme, World Health Organization, Geneva, Switzerland.
Howard NjooCentre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Montreal, QC, Canada.
Ivan SolovicTB Dept, National Institute for TB, Respiratory Diseases and Thoracic Surgery, Vysne Hagy, Catholic University, Ružomberok, Slovakia.
Alistair StoryFind and Treat, London, UK.
Tamara TayebNational TB Control Programme, Ministry of Health, Riyadh, Saudi Arabia.
Marieke J van der WerfEuropean Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
Diana WeilGlobal TB Programme, World Health Organization, Geneva, Switzerland.
Jean-Pierre ZellwegerSwiss Lung Association, Bern, Switzerland.
Mohamed Abdel AzizWHO Regional Office for the Eastern Mediterranean, Cairo, Egypt.
Mohamed R M Al LawatiMinistry of Health, Muscat, Oman.
Stefano AlibertiUniversità degli Studi di Milano - Bicocca, UO Clinica Pneumologica, AO San Gerardo, Monza, Italy.
Wouter Arrazola de OñateBelgian Lung and Tuberculosis Association, Brussels, Belgium.
Draurio BarreiraMinistry of Health, Brasilia, Brazil.
Vineet BhatiaGlobal TB Programme, World Health Organization, Geneva, Switzerland.
Francesco BlasiDipartimento Fisiopatologia Medico-Chirurgica e dei Trapianti, University of Milan, IRCCS Fondazione Cà Granda, Milan, Italy.
Amy BloomUS Agency for International Development, Washington, DC, USA.
Judith BruchfeldUnit of Infectious Diseases, Institution of Medicine, Karolinska Institute Solna and Karolinska University Hospital, Stockholm, Sweden.
Francesco CastelliUniversity of Brescia, Brescia, Italy.
Rosella CentisWHO Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, IRCCS, Tradate, Italy.
Daniel ChemtobMinistry of Health, Jerusalem, Israel.
Daniela M CirilloIRCCS San Raffaele Scientific Institute, Milan, Italy.
Alberto ColoradoAdvocates for Health International, San Diego, CA, USA.
Andrei DaduTB and M/XDR-TB Control Programme, WHO Regional Office for Europe, Copenhagen, Denmark.
Ulf R DahleNorwegian Institute of Public Health, Oslo, Norway.
Laura De PaoliMédecins sans Frontières, Rome, Italy.
Hannah M DiasGlobal TB Programme, World Health Organization, Geneva, Switzerland.
Raquel DuarteGeneral Directorate of Health, Lisbon, Portugal.
Lanfranco FattoriniIstituto Superiore di Sanita, Rome, Italy.
Mina GagaNational Referral Centre for Mycobacteria, Athens Chest Hospital, Ministry of Health, Athens, Greece.
Haileyesus GetahunGlobal TB Programme, World Health Organization, Geneva, Switzerland.
Philippe GlaziouGlobal TB Programme, World Health Organization, Geneva, Switzerland.
Lasha GoguadzeInternational Federation of Red Cross and Red Crescent Societies, Geneva, Switzerland.
Mirtha Del GranadoWHO Regional Office for the Americas, Washington, DC, USA.
Walter HaasDept of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
Asko JärvinenFinnish Lung Health Association, Helsinki, Finland Helsinki University Central Hospital, Division of Infectious Diseases, Helsinki, Finland.
Geun-Yong KwonKorea Centers for Disease Control and Prevention (KCDC), Ministry of Health and Welfare, Seoul, Republic of Korea.
Davide MoscaInternational Organization for Migration, Geneva, Switzerland.
Payam NahidUniversity of California, San Francisco, CA, USA American Thoracic Society (ATS), New York, NY, USA.
Nobuyuki NishikioriStop TB and Leprosy Elimination, WHO Regional Office for the Western Pacific, Manila, Philippines.
Isabel NoguerInstituto de Salud Carlos III, Madrid, Spain.
Joan O'DonnellHSE Health Protection Surveillance Centre, Dublin, Ireland.
Analita Pace-AsciakMinistry for Health, Valletta, Malta.
Maria G PompaMinistry of Health, Rome, Italy.
Gilda G PopescuPneumology Institute Marius Nasta, Bucharest, Romania.
Carlos Robalo CordeiroCoimbra University Hospital, Coimbra, Portugal.
Karin RønningNorwegian Institute of Public Health, Oslo, Norway.
Morten RuhwaldStatens Serum Institut (SSI), Copenhagen, Denmark.
Jean-Paul SculierInstitut Jules Bordet (ULB), Brussels, Belgium.
Aleksandar SimunovićCroatian National Institute of Public Health, Zagreb, Croatia.
Alison Smith-PalmerHealth Protection Scotland, Glasgow, UK.
Giovanni SotgiuClinical Epidemiology and Medical Statistics Unit, Dept of Biomedical Sciences, University of Sassari, Research, Medical Education and Professional Development Unit, AOU Sassari, Sassari, Italy.
Giorgia SulisGlobal TB Programme, World Health Organization, Geneva, Switzerland.
Carlos A Torres-DuqueAsociacion Latinoamericana de Torax (ALAT) - Fundacion Neumologica Colombiana, Bogota, Colombia.
Kazunori UmekiMinistry of Health, Labour and Welfare, Tokyo, Japan.
Mukund UplekarGlobal TB Programme, World Health Organization, Geneva, Switzerland.
Catharina van WeezenbeekKNCV Tuberculosis Foundation, The Hague, The Netherlands.
Tuula VasankariFinnish Lung Health Association, Helsinki, Finland.
Robert J VitilloCaritas Internationalis, Geneva, Switzerland.
Constantia VoniatisMinistry of Health, Nicosia, Cyprus.
Maryse WanlinFonds des Affections Respiratoires (FARES), Brussels, Belgium.
Mario C RaviglioneGlobal TB Programme, World Health Organization, Geneva, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This paper describes an action framework for countries with low tuberculosis (TB) incidence (<100 TB cases per million population) that are striving for TB elimination. The framework sets out priority interventions required for these countries to progress first towards "pre-elimination" (<10 cases per million) and eventually the elimination of TB as a public health problem (less than one case per million). TB epidemiology in most low-incidence countries is characterised by a low rate of transmission in the general population, occasional outbreaks, a majority of TB cases generated from progression of latent TB infection (LTBI) rather than local transmission, concentration to certain vulnerable and hard-to-reach risk groups, and challenges posed by cross-border migration. Common health system challenges are that political commitment, funding, clinical expertise and general awareness of TB diminishes as TB incidence falls. The framework presents a tailored response to these challenges, grouped into eight priority action areas: 1) ensure political commitment, funding and stewardship for planning and essential services; 2) address the most vulnerable and hard-to-reach groups; 3) address special needs of migrants and cross-border issues; 4) undertake screening for active TB and LTBI in TB contacts and selected high-risk groups, and provide appropriate treatment; 5) optimise the prevention and care of drug-resistant TB; 6) ensure continued surveillance, programme monitoring and evaluation and case-based data management; 7) invest in research and new tools; and 8) support global TB prevention, care and control. The overall approach needs to be multisectorial, focusing on equitable access to high-quality diagnosis and care, and on addressing the social determinants of TB. Because of increasing globalisation and population mobility, the response needs to have both national and global dimensions.

Indexed as

Developed CountriesGlobal HealthAntitubercular AgentsCommunicable Disease ControlFemaleHumansIncidenceInternational CooperationMaleOrganizational InnovationTuberculosisTuberculosis, Multidrug-ResistantAntitubercular Agents

Identifiers

PMID25792630
PMCPMC4391660

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.